Levodopa-Benserazid Teva

Levodopa, the active ingredient in Levodopa-Benserazid Teva, is an antiparkinson agent presented as an oral tablet for oral use. It is combined with benserazide to increase central dopamine availability and is indicated for the treatment of Parkinson's disease symptoms in adult patients.

GNH USA supplies Levodopa-Benserazid Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality through stringent manufacturing standards and regulatory compliance across EU markets.

Levodopa/benserazide is used in the management of Parkinsonian disorders, targeting dopaminergic deficiency.

- Parkinson's disease: reduces motor symptoms such as bradykinesia, rigidity, and tremor. - Early-stage Parkinson's disease: improves initial motor function and delays progression of symptoms. - Advanced Parkinson's disease with motor fluctuations: smooths out on‑off periods and enhances overall mobility.

Levodopa/benserazide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Severe hypotension - Cardiac arrhythmias - Anaphylactic reactions

When prescribing Levodopa/benserazide, several precautions should be observed to ensure safe use.

- Dose titration: start low and increase gradually to minimize gastrointestinal side effects. - Cardiovascular monitoring: watch for orthostatic hypotension and arrhythmias. - Psychiatric monitoring: assess for hallucinations or mood changes. - Renal/hepatic impairment: adjust dosing in patients with significant organ dysfunction. - Concomitant MAO‑B inhibitors: avoid or use with caution due to increased levodopa levels. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Levodopa/benserazide can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Dopamine antagonists (e.g., typical antipsychotics): may reduce therapeutic effect. - Iron or calcium supplements taken simultaneously: decrease levodopa absorption.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (e.g., selegiline): may increase levodopa plasma levels. - Anticholinergic agents: can enhance central side effects. - Antihypertensive drugs: additive blood pressure‑lowering effect. - SSRIs or SNRIs: monitor for serotonin syndrome risk.